Plain-English translation of NCT02610439 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study uses genetic testing to understand why some breast cancer patients develop nerve damage (called peripheral neuropathy) after receiving paclitaxel chemotherapy, while others do not. Researchers will examine DNA samples that were already collected from patients in a previous breast cancer trial to identify genetic variations that may make someone more likely to experience this side effect. The goal is to eventually help doctors predict and prevent this painful complication in future patients.
Nerve damage is a common and serious side effect of paclitaxel chemotherapy that can cause long-term pain and disability. By identifying which genetic factors increase the risk, doctors may one day be able to warn patients in advance or find ways to protect them from this complication.
You likely qualify if…
You likely don't qualify if…
This is a straightforward genetic study—you do not need to visit a clinic or take any new medication. Researchers will simply analyze your DNA sample that was already collected during your original breast cancer treatment study. There are no additional blood draws, appointments, or tests required from you; the study uses only samples and information that already exist from your past care.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
United States
Sponsor
National Cancer Institute (NCI)
Enrollment target
~575 participants
Started
March 2014
Primary completion
January 2100
Last updated on clinicaltrials.gov in March 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.